01 / What it is
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist and a metabolite-derived analog of Melanotan II. Unlike its parent compound, it is studied primarily for central rather than pigmentation signaling.
Research use onlySpecification publishedQualified users only
Dermal, matrix & melanocortin research · AGX-15
PT-141
The melanocortin receptor agonist
$50
10 mg lyophilized vial$5.00/mg · research use only
Research use only · no human or veterinary use, consumption, administration, diagnosis, treatment, prevention, cosmetic use, or food use. Sold to qualified laboratory and analytical users.
02 / Mechanism in the literature
Replacing the C-terminal amide with a carboxylic acid shifts its receptor profile toward MC4R and away from the MC1R pigmentation signaling that characterizes Melanotan II. MC4R is expressed in the central nervous system, which is where the research literature focuses.
03 / Research context
PT-141 appears in melanocortin-receptor and neuroendocrine signaling literature as an MC4R-preferring analog.
Listed format10 mg lyophilized vial
SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular formulaC50H68N14O10
Molecular weight1025 g/mol
Catalogue referenceAGX-15
Listed price$50
TargetMC4R
04 / Common questions
How does PT-141 differ from Melanotan II?
A single C-terminal change — amide to carboxylic acid — shifts the receptor preference toward MC4R and away from the MC1R pigmentation pathway.
What does MC4R-preferring mean?
It binds several melanocortin receptors but shows greater relative activity at MC4R, which is the subtype the research literature concentrates on.